Research programme: cardiovascular and metabolic diseases therapeutics - Deargen
Alternative Names: DG-HF-T1; DG-HL-T1Latest Information Update: 16 Mar 2022
At a glance
- Originator Deargen
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 01 Mar 2022 Early research in Cardiovascular disorders in South Korea (unspecified route) (Deargen pipeline March 2022)
- 01 Mar 2022 Early research in Metabolic disorders in South Korea (unspecified route) (Deargen pipeline March 2022)